Mastodon

Novalgin® (Tablets) Instructions for Use

ATC Code

N02BE51 (Paracetamol in combination with other drugs, excluding psycholeptics)

Active Substances

Caffeine (Ph.Eur. European Pharmacopoeia)

Paracetamol (Rec.INN WHO registered)

Propyphenazone (Rec.INN WHO registered)

Clinical-Pharmacological Group

Combination analgesic-antipyretic

Pharmacotherapeutic Group

Analgesics; other analgesics and antipyretics; anilides

Pharmacological Action

A combined medicinal product. The combination of the three components of the drug leads to a mutual enhancement of their pharmacological action.

Paracetamol and Propyphenazone have analgesic and antipyretic effects. Paracetamol is a non-narcotic analgesic. It blocks COX only in the CNS, affecting the centers of pain and thermoregulation (in inflamed tissues, cellular peroxidases neutralize the effect of paracetamol on COX), which explains the almost complete absence of an anti-inflammatory effect. The lack of effect on the synthesis of prostaglandins (PG) in peripheral tissues determines the absence of a negative effect on water-salt metabolism (sodium and water retention) and the gastrointestinal mucosa.

Propyphenazone is a pyrazolone derivative. The mechanism of action is carried out by inhibiting COX, which is involved in the formation of prostaglandins from arachidonic acid.

Caffeine increases the reflex excitability of the spinal cord, excites the respiratory and vasomotor centers, dilates the blood vessels of skeletal muscles, brain, heart, kidneys, reduces platelet aggregation; reduces drowsiness, feeling of fatigue. In this combination, Caffeine in a small dose has practically no stimulating effect on the CNS, but contributes to the regulation of cerebral vascular tone, reduces drowsiness, and enhances the analgesic effect of other components of the drug.

Pharmacokinetics

Paracetamol

Absorption is high, plasma protein binding is 15%, Tmax is 20-30 min. Penetrates the BBB. Less than 1% of the dose taken by a nursing mother penetrates into breast milk. The therapeutic effective concentration of paracetamol in plasma is achieved when it is prescribed at a dose of 10-15 mg/kg.

Metabolized in the liver: 80% undergoes a conjugation reaction with glucuronic and sulfuric acids to form inactive metabolites; 17% undergoes hydroxylation to form inactive metabolites, which conjugate with glutathione and form inactive metabolites. With a lack of glutathione, these metabolites can block the enzyme systems of hepatocytes and cause their necrosis. T1/2 is 2-3 hours. In elderly patients, the clearance of paracetamol decreases and the half-life increases. Excreted by the kidneys unchanged 3%.

Propyphenazone

Cmax of propyphenazone in plasma is reached after 30 min. Metabolized in the liver. T1/2 is 1-1.5 hours. Combination with paracetamol increases its elimination time by 40%, which plays a significant role, as it allows to reduce the number of drug doses per day. Excreted by the kidneys.

Caffeine

Time to reach Cmax – 1 hour; T1/2 – 3.5 hours; 65-80% of caffeine is excreted by the kidneys mainly in the form of 1-methylxanthine, 1-methyluric acid and acetylated uracil derivatives, a small amount is converted to theophylline and theobromine.

Indications

Relief of mild to moderate pain of various origins: headache; migraine; toothache; arthralgia; myalgia; algodysmenorrhea.

As an antipyretic for febrile conditions against the background of infectious and inflammatory diseases (ARVI, including influenza, etc.).

ICD codes

ICD-10 code Indication
G43 Migraine
J06.9 Acute upper respiratory infection, unspecified
J10 Influenza due to identified seasonal influenza virus
K08.8 Other specified disorders of teeth and supporting structures (including toothache)
M25.5 Pain in joint
M79.1 Myalgia
N94.4 Primary dysmenorrhea
N94.5 Secondary dysmenorrhea
R50 Fever of unknown origin
R51 Headache
R52.0 Acute pain
R52.2 Other chronic pain
ICD-11 code Indication
1E30 Influenza due to identified seasonal influenza virus
8A80.Z Migraine, unspecified
8A8Z Headache disorders, unspecified
CA07.0 Acute upper respiratory tract infection of unspecified site
DA0A.Z Diseases of teeth and supporting structures, unspecified
FB56.2 Myalgia
GA34.3 Dysmenorrhea
LA30.5Z Anomalies of tooth resorption or loss, unspecified
ME82 Pain in joint
MG26 Fever of other or unknown origin
MG30.Z Chronic pain syndrome, unspecified
MG31.Z Acute pain, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Take tablets orally, after meals, with a small amount of liquid.

For adults, administer 1-2 tablets up to 4 times a day as needed for pain or fever.

Do not exceed a maximum daily dose of 6 tablets.

For children aged 12 to 18 years, administer 1 tablet up to three times a day.

Limit the duration of use to no more than 3 days for antipyretic purposes.

Limit the duration of use to no more than 5 days for analgesic purposes.

Do not use in children under 12 years of age.

Use with caution in elderly patients and adjust dosage if necessary.

If symptoms persist beyond the recommended treatment duration, consult a physician for re-evaluation.

Avoid concomitant use with other products containing paracetamol or caffeine to prevent overdose.

Adverse Reactions

From the nervous system dizziness, insomnia.

From the gastrointestinal tract nausea, vomiting, heaviness and discomfort in the stomach area;

From the hematopoietic system thrombocytopenia, agranulocytosis, hemolytic anemia.

Allergic reactions skin rash, itching, urticaria, angioedema, multiforme exudative erythema (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome).

Contraindications

Hypersensitivity to the components of the drug; severe renal and/or hepatic insufficiency; deficiency of the enzyme glucose-6-phosphate dehydrogenase; inhibition of bone marrow hematopoiesis (leukopenia, anemia, including hemolytic); acute hematoporphyria; complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to NSAIDs (including history); conditions accompanied by respiratory depression; intracranial hypertension; acute myocardial infarction; coronary artery disease; arrhythmias; arterial hypertension; peptic ulcer of the stomach and duodenum; glaucoma; insomnia; pregnancy; lactation; children under 12 years of age.

With caution benign hyperbilirubinemia (including Gilbert’s syndrome, Dubin-Johnson syndrome, Rotor syndrome), old age, alcoholism, epilepsy and a tendency to convulsive seizures.

Use in Pregnancy and Lactation

Contraindicated during pregnancy and lactation (breastfeeding).

Use in Hepatic Impairment

Contraindicated in severe hepatic insufficiency.

Use in Renal Impairment

Contraindicated in severe renal insufficiency.

Pediatric Use

Contraindication: children under 12 years of age.

Geriatric Use

With caution: old age.

Special Precautions

With long-term use (more than 5 days), monitoring of the peripheral blood picture and the functional state of the liver is necessary.

During treatment, one should refrain from consuming alcoholic beverages (increased risk of gastrointestinal bleeding).

Excessive consumption of caffeine-containing products (coffee, tea) during treatment may cause overdose symptoms.

Taking the drug may complicate the diagnosis in acute abdominal pain syndrome.

Effect on ability to drive vehicles and mechanisms

During the reception, caution should be exercised when driving vehicles and engaging in other activities that require increased concentration and speed of psychomotor reactions.

Drug Interactions

The effectiveness of this combination may decrease with simultaneous use with cholestyramine, anticholinergics, antidepressants, alkaline substances.

With simultaneous use with barbiturates, anticonvulsants, ethanol, the hepatotoxic effect is significantly increased.

Metoclopramide accelerates the absorption of paracetamol.

Under the influence of paracetamol, the half-life of chloramphenicol increases by 5 times.

Simultaneous use of paracetamol in high doses enhances the effect of anticoagulants.

Myelotoxic agents enhance the manifestations of hematotoxicity of paracetamol.

Caffeine accelerates the absorption of ergotamine; reduces the absorption of calcium preparations; reduces the effect of narcotic and hypnotic drugs, increases the excretion of lithium preparations; accelerates the absorption and enhances the effect of cardiac glycosides, increases their toxicity.

Simultaneous use of caffeine with beta-blockers may lead to mutual suppression of therapeutic effects, with beta-agonists to additional stimulation of the CNS and other toxic effects.

Caffeine may reduce the clearance of theophylline, and possibly other xanthines, increasing the possibility of additive pharmacodynamic and other toxic effects.

MAO inhibitors, furazolidone, procarbazine, selegiline and large doses of caffeine may cause the development of dangerous cardiac arrhythmias or a marked increase in blood pressure.

Nicotine increases the rate of caffeine excretion.

Caffeine is an antagonist of adenosine.

Propyphenazone may enhance the effect of oral hypolipidemic agents, sulfonamide drugs, anticoagulants, the ulcerogenic effect of glucocorticosteroids, reduces the effectiveness of potassium-sparing diuretics.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Alvils Patent, LLC (Russia)

Manufactured By

Styrolbiopharm LLC (Ukraine)

Dosage Form

Bottle OTC Icon Novalgin® Tablets 200 mg+200 mg+50 mg: 6, 12, 24, or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets 1 tab.
Paracetamol 200 mg
Propyphenazone 200 mg
Caffeine 50 mg

6 pcs. – blisters (1) – cardboard packs.
12 pcs. – blisters (1) – cardboard packs.
12 pcs. – blisters (2) – cardboard packs.
30 pcs. – polymer containers (1) – cardboard packs.

Marketing Authorization Holder

Alvils, LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Bottle OTC Icon Novalgin® Tablets 50 mg+200 mg+200 mg: 6, 10, 12, 20, 24, 30, 48, or 60 pcs.

Dosage Form, Packaging, and Composition

Tablets from white to white with a yellowish tint, round, flat-cylindrical, with a score on one side and bevels on both sides; marbling is allowed.

1 tab.
Caffeine 50 mg
Paracetamol 200 mg
Propyphenazone 200 mg

Excipients: microcrystalline cellulose – 100 mg, croscarmellose sodium – 8 mg, sodium starch glycolate (type A) – 44.8 mg, povidone K25 – 18 mg, colloidal silicon dioxide – 3.2 mg, magnesium stearate – 16 mg.

6 pcs. – contour cell packs (1) – cardboard packs.
6 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
12 pcs. – contour cell packs (1) – cardboard packs.
12 pcs. – contour cell packs (2) – cardboard packs.
24 pcs. – contour cell packs (1) – cardboard packs.
24 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.
60 pcs. – jars (1) – cardboard packs.

TABLE OF CONTENTS